Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
anti-CD19 CAR T-cells (UCL)
- Development stage
- Unknown
- Lead developer
- Autolus Therapeutics
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Administration
- Intravenous
01
Overview
Investigational autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy developed at University College London (UCL). This biologic immunotherapy involves the genetic modification of a patient's own T lymphocytes to express a CAR that targets the CD19 protein, a surface marker found on B-cell lymphomas. The CAR construct utilizes an FMC63-derived single-chain variable fragment (scFv) for antigen recognition. The therapy is currently being evaluated in the Phase 1 COBALT clinical trial, which investigates its safety and efficacy as a bridge to allogeneic stem cell transplantation in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who have failed or are ineligible for autologous stem cell transplant.
- Other names
- CD19-specific CAR T-cellsCD-19-specific CAR T-cellsCD 19-specific CAR T-cellsUCL CAR19
02
Targets
CD19 (B lymphocyte antigen CD19)CD22 (Cluster of Differentiation 22)
Beyond the preview
Go deeper on anti-CD19 CAR T-cells (UCL).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on anti-CD19 CAR T-cells (UCL).